All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Top Biopharma Trends of 2021
    • Top Med-tech Trends of 2021
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, July 6, 2022
Home » Authors » Marie Powers

Articles by Marie Powers

Regulatory front for Feb. 5, 2021

Feb. 5, 2021
By Marie Powers
No Comments
The latest global regulatory news, changes and updates affecting medical devices and technologies, including: EMA initiates OPEN collaboration; NICE evaluating guidance processes; Florida researcher indicted.
Read More
Health professional touching screen, digital/medical icons
AI partnerships ‘move the industry forward’

Trial recruitment, retention improved but drop-outs persist in late studies

Feb. 11, 2020
By Marie Powers
No Comments
Multiple tactics employed by the biopharma industry to improve the recruitment and retention of participants in clinical trials seem to be paying off. More than three of four (77%) studies now fully enroll on or ahead of schedule, according to researchers at the Tufts Center for the Study of Drug Development (CSDD), reporting in the January/February Tufts CSDD Impact Report on global recruitment performance benchmarks.
Read More

WARF Therapeutics rewriting drug discovery rules at legendary TTO

Dec. 24, 2019
By Marie Powers
No Comments
More than a decade after one of its early splashes in therapeutic development caused ripples in the U.S. patent tide pool, the Wisconsin Alumni Research Foundation, better known as WARF, is taking a more seasoned approach to drug discovery and development.
Read More

Neurology ‘adapting’ to oncology model with new trial design

Nov. 4, 2019
By Marie Powers
No Comments
The oncology field pioneered adaptive trial designs through efforts such as I-SPY 2 (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2), Puma Biotechnology Inc.’s phase II study of the pan-HER tyrosine kinase inhibitor neratinib (Nerlynx) as neoadjuvant therapy in metastatic breast cancer, and the ongoing multidrug, biomarker-driven non-small-cell lung cancer trial known as Lung-MAP.
Read More

Small-molecule RNA fixes aiming to drug the undruggable

Sep. 3, 2019
By Marie Powers
No Comments
Two recent deals signaled to the industry that efforts to target previously undruggable RNA with small-molecule therapies may be moving from academic endeavor to fruitful application.
Read More

Exscientia, Rallybio rev rare drug discovery engine with RE Ventures

Aug. 30, 2019
By Marie Powers
No Comments
A year after landing a $37 million series A to support its mission of addressing the most desperate of rare diseases, Rallybio LLC linked up with Exscientia Ltd. to form RE Ventures, a joint venture designed to accelerate the discovery of small-molecule drug therapies targeting rare disease indications.
Read More

Decade of discovery leads to cardiovascular gene therapy effort

Aug. 15, 2019
By Marie Powers
No Comments
Nearly a decade in the making, Philadelphia-based Renovacor Inc. set sail with its first institutional raise. The company closed an $11 million series A co-led by Novartis Venture Fund, Broadview Ventures and Bioadvance and joined by New Leaf Venture Partners and Italy-based Innogest Capital.
Read More

No 'Rest' for DED as blockbuster wannabes jockey for lead

June 28, 2019
By Marie Powers
No Comments
The hunt is on for a dry eye disease (DED) therapy to replace Allergan plc's blockbuster, Restasis (ciclosporin), which the Dublin-based firm sought to shield behind the protective estate of 27 patents, including six famously assigned in 2017 to the Saint Regis Mohawk Tribe and then licensed back in perpetuity, seeking to prevent their expiry in 2024. 
Read More

No 'Rest' for DED as blockbuster wannabes jockey for lead

June 24, 2019
By Marie Powers
No Comments
The hunt is on for a dry eye disease (DED) therapy to replace Allergan plc's blockbuster, Restasis (ciclosporin), which the Dublin-based firm sought to shield behind the protective estate of 27 patents, including six famously assigned in 2017 to the Saint Regis Mohawk Tribe and then licensed back in perpetuity, seeking to prevent their expiry in 2024. 
Read More

Beyond ‘beta’ testing: Thalassemia pipeline marching toward market

May 31, 2019
By Marie Powers
No Comments
The hematology world is a-twitter about the imminent approval of Zynteglo (betibeglogene darolentivec), the lentiglobin cell and gene therapy from Bluebird Bio Inc. that’s expected to become the first gene therapy to address the blood disease beta-thalassemia and the company’s first product to market. 
Read More
Previous 1 2 3 4 5 6 7 8 9 … 168 169 Next

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld

    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 6, 2022.
  • Novavax-COVID-19-vaccine-vial

    Novavax vaccine shows its chops

    BioWorld
    Given that Novavax Inc.’s COVID-19 vaccine will be a latecomer to the U.S. scene if it gets FDA authorization, it’s been cast in a supporting role to the lead...
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech's briefs for July 6.
  • Blood sample, DNA

    Biomarin outlines pricing strategy for costly hemophilia A gene therapy after backing from European regulators

    BioWorld
    The first gene therapy to treat severe hemophilia A was among the drugs recommended for European approval by regulators from the EMA’s CHMP at its monthly...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Archives
    • Today's news
    • Search BioWorld Science
    • About
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing